Non-Small Cell Lung Cancer Activities

PROGRAM CHAIR

Beth Eaby-Sandy, MSN, CRNP, OCN®
Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania • Philadelphia, Pennsylvania


These educational activities are supported by educational grants from AstraZeneca, Clovis Oncology, Lilly, and Merck & Co.

Use of Diagnostic Tests in Advanced Non–Small Cell Lung Cancer: Skills Presentation

The scope of knowledge and skills required to safely manage oncology patients today is daunting. Personalized medicine is becoming the standard of care as new molecular/genetic testing becomes available. This activity will provide advanced practitioners with an overview of histologic and molecular differentiation in the diagnosis and staging of non–small cell lung cancer, and how to apply that knowledge to the ordering and interpretation of diagnostic and molecular testing. 

Posted: 9/27/2016                     Expires: 5/30/2017

Credits/Contact Hours: 0.25

Access the Activity for Credit*
   
Participate Without Claiming Credit

* This link will take you to the
Meniscus Educational Institute website.


Management of Patients With Cytotoxic Chemotherapy

This activity will provide advanced practitioners with valuable insights into cytotoxic chemotherapy treatment strategies for patients with non–small cell lung cancer of both squamous and non-squamous histology. Discussions include first-line treatment options, treatment considerations in the elderly patient, maintenance chemotherapy, second-line therapy, and more.

Posted: 9/27/2016                     Expires: 5/30/2017

Credits/Contact Hours: 0.50

Access the Activity for Credit*
   
Participate Without Claiming Credit

* This link will take you to the
Meniscus Educational Institute website.


Targeted Therapies in Advanced Non–Small Cell Lung Cancer

Knowledge of the molecular biology of tumors is rapidly evolving. As a result, new targets for treatments are increasing the arsenal for treating advanced non–small cell lung cancer. This activity provides an update on newer targeted treatment strategies, including rationale/target, mechanisms of action, potential toxicities, and symptom management of targeted therapies.

Posted: 9/27/2016                     Expires: 5/30/2017

Credits/Contact Hours: 0.75

Access the Activity for Credit*
   
Participate Without Claiming Credit

* This link will take you to the
Meniscus Educational Institute website.


Management of Patients Treated With Immunotherapy

Immunotherapy, one of the most important breakthroughs for cancer treatment in the past decade, is demonstrating its effectiveness across tumor types, including non–small cell lung cancer. This activity will provide information on the newest agents in the armamentarium for treating non–small cell lung cancer, including PD-1 inhibitor, and anti-CTLA4 immunotherapy. In addition, the discussion will include the recognition and management of potential immune-mediated adverse events unique to immune checkpoint inhibitors.

Posted: 9/27/2016                     Expires: 5/30/2017

Credits/Contact Hours: 0.25

Access the Activity for Credit*
   
Participate Without Claiming Credit

* This link will take you to the
Meniscus Educational Institute website.


Copyright © 2016 Harborside Press, LLC All rights reserved.                Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact
Copyright Notice/Disclaimer
Bot trap - Don't go here
click me